Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society
Avacta Therapeutics (AIM: AVCT) Preliminary Data in Faridoxorubicin Phase 1b Trial
Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort
Welcome Dr. Christina Coughlin, CEO of Avacta Therapeutics, onto The BioHub!
Welcome to the Avetix Group YouTube channel.
Avacta Therapeutics (AIM: AVCT) Presents preclinical data at AACR-NCI-EORTC
Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
Avacta Impresses at ESMO with Positive Phase 1a Data for pre|CISION® Platform
Avacta Therapeutics presents compelling Phase 1a data for faridoxorubicin and the pre|CISION® platform at the European Society of Medical Oncology Annual Congress
Avacta Unveils Data on First Dual-Payload Peptide Drug Conjugate at International Cancer Conference
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
Avacta’s pre|CISION® Platform Shortlisted for AIM Technology of the Year
Avacta Group plc has announced that its proprietary pre|CISION® platform has been shortlisted for the AIM Technology of the Year Award.
Avacta Secures £3.25m Through Oversubscribed Placing and Amends Convertible Bond
Avacta Group PLC has announced a successful conditional equity fundraise, raising gross proceeds of £3.25 million through an oversubscribed placing. The placing comprised 6,500,000 new ordinary shares issued at 50
Avacta Therapeutics (AIM: AVCT) Announces Agreement to Sell Coris Bioconcept SRL
Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announced the sale of Coris Bioconcept SRL (“Coris”) to 3B BlackBio Dx Ltd for an upfront cash consideration of £2.15 Million
Avacta (AIM: AVCT) Equity fundraise of £3.25 million
Avacta (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, is pleased to announce that it has raised gross proceeds of £3.25 million from long term, high net worth
Avacta Group PLC (AIM: AVCT) Q2 2025 Business Update
Outlining Progress Against Strategic Objectives
Avacta Group PLC (AIM:AVCT) Management Team Appointments
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development